1. Home
  2. CAPR vs PBPB Comparison

CAPR vs PBPB Comparison

Compare CAPR & PBPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPR
  • PBPB
  • Stock Information
  • Founded
  • CAPR 2005
  • PBPB 1977
  • Country
  • CAPR United States
  • PBPB United States
  • Employees
  • CAPR N/A
  • PBPB N/A
  • Industry
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • PBPB Restaurants
  • Sector
  • CAPR Health Care
  • PBPB Consumer Discretionary
  • Exchange
  • CAPR Nasdaq
  • PBPB Nasdaq
  • Market Cap
  • CAPR 324.6M
  • PBPB 305.0M
  • IPO Year
  • CAPR N/A
  • PBPB 2013
  • Fundamental
  • Price
  • CAPR $6.28
  • PBPB $12.94
  • Analyst Decision
  • CAPR Strong Buy
  • PBPB Strong Buy
  • Analyst Count
  • CAPR 8
  • PBPB 2
  • Target Price
  • CAPR $24.75
  • PBPB $17.50
  • AVG Volume (30 Days)
  • CAPR 1.4M
  • PBPB 257.0K
  • Earning Date
  • CAPR 08-11-2025
  • PBPB 08-06-2025
  • Dividend Yield
  • CAPR N/A
  • PBPB N/A
  • EPS Growth
  • CAPR N/A
  • PBPB N/A
  • EPS
  • CAPR N/A
  • PBPB 0.35
  • Revenue
  • CAPR $13,392,150.00
  • PBPB $469,138,000.00
  • Revenue This Year
  • CAPR N/A
  • PBPB $5.28
  • Revenue Next Year
  • CAPR $6,061.53
  • PBPB $4.30
  • P/E Ratio
  • CAPR N/A
  • PBPB $37.36
  • Revenue Growth
  • CAPR N/A
  • PBPB N/A
  • 52 Week Low
  • CAPR $3.98
  • PBPB $7.27
  • 52 Week High
  • CAPR $23.40
  • PBPB $13.67
  • Technical
  • Relative Strength Index (RSI)
  • CAPR 36.33
  • PBPB 57.95
  • Support Level
  • CAPR $6.17
  • PBPB $12.78
  • Resistance Level
  • CAPR $7.30
  • PBPB $13.18
  • Average True Range (ATR)
  • CAPR 0.43
  • PBPB 0.38
  • MACD
  • CAPR -0.11
  • PBPB 0.05
  • Stochastic Oscillator
  • CAPR 4.53
  • PBPB 81.10

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About PBPB Potbelly Corporation

Potbelly Corp owns and franchises hundreds of limited-service restaurants specializing in sandwiches and salads, shakes. The menu includes toasty sandwiches, signature salads, soups, chili, sides, desserts, and, in breakfast locations it serves breakfast sandwiches and steel-cut oatmeal. majority of its locations are company-owned and located in the United States, with Illinois and Texas housing far more locations than any other state. The company has franchise partners in a number of countries. Excluding the United States, its franchises are in the Middle East.

Share on Social Networks: